Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Company Profile

Stronger Sell Today AGIO ranks #4876 as SELL CANDIDATE #4876 Weaker Sell

AGIO stock forecast Agios Pharmaceuticals

AGIO stock forecast

Agios Pharmaceuticals

88 Sidney Street

Cambridge, MA 02139

617-649-8600

www.agios.com

Industry: Biotechnology

Sector: Healthcare


Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company’s product candidates include AG-221, an potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II, Phase Ib combination, and Phase III IDHENTIFY clinical trials for the treatment of hematologic malignancies, as well as is in Phase 1/2 clinical trial for treating solid tumors, including AITL. Its product candidates also comprise AG-120, an potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical and Phase Ib combination clinical trials for the treatment of hematologic malignancies, as well as Phase I clinical trial for treating solid tumors; and AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors. In addition, the company is involved in developing AG-348, an potent activator that is in Phase II DRIVE PK clinical trial; and AG-519 potent activator that are in Phase I clinical trial for treating patients with pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and with Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank